Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
20 participants
INTERVENTIONAL
2019-09-01
2025-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Treatment
* 60 Gy/50 fx / 10W-1 at 1.2 Gy/fx
o i.e. EQD2 tumor=56 Gy, EQD2 late=50.4 Gy at α/β= 10 and 3, respectively
* Proton radiotherapy
* Concomitant cisplatin for eligible patients\*
* Nimorazole recommended for SCC\* \*The concurrent medical treatment (weekly cisplatin and nimorazole) are prescribed according to the national treatment guidelines, and are not part of the experimental treatment.
Endpoints
* Primary:
o Any new late toxicity grade \>=3 according to CTC AE 5.0
* Secondary
* Side effects according to DAHANCA scoring system
* Quality of life and PROM according to EORTC C30 and HN43
* Loco-regional control (LRC)
* Overall survival (OS)
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification of Radiotherapy of HNSCC.
NCT02661152
DAHANCA 35: Proton Versus Photon Therapy for Head-neck Cancer
NCT04607694
A Safety and Efficacy Study for Combinational Treatment of DaRT and Check Point Inhibitor for Recurrent Unresectable or mHNSCC
NCT05047094
Feasibility of Patient Selection and Treatment of Head-neck Cancer With Proton Therapy in Denmark
NCT05423704
Proton Re-Irradiation for Recurrent Head and Neck Cancer
NCT03217188
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Histological verified loco-regional recurrence or new primary
* Available dose plan from primary radiotherapy course
* Comparative dose plan with advantages for proton radiotherapy e.g. integral dose
* Dmax dose (0.03 cm3) on the cumulated photon dose plan≥90 Gy
* Complete Response (CR)\* after initial therapy, except in the case where the recurrence is considered a geometric miss (recurrence center of mass (COM) outside the 95% of prescription dose.
* Inoperable or salvage surgery with R1/R2 resection, extranodal extension (ENE) or extensive soft tissue infiltration
* Absence of distant metastasis at both
* clinical examination AND
* PET-CT or CT of thorax and upper abdomen
* Life expectancy due to age and co-morbidity of \>=1 year. The general condition must be sufficient to tolerate persistent significant side effects, e.g. tube or cannulae
* PS\<=2 (WHO See appendix)
* The patients should be able to read Danish in order to participate with quality of life questionnaires, but can participate in the rest of the protocol without being fluent in Danish, if capable of reading the patient information.
\* Complete Response is defined as the situation when a trained clinician, ideally at a multidisciplinary team conference, defines the patient as in complete remission, based on clinical examination and available imaging. This status can of course later be considered wrong as new information becomes available (sub-centimeter nodes grow etc.) Exclusion criteria
* Radical surgery (R0) and absence of adverse prognostic pathological features
* Lymphoma or malignant melanoma
* Inability to attend full course of radiotherapy or follow-up visits in the outpatient clinic
* As of 2019, patients with tracheal cannulas are excluded due to dose uncertainties. This may change if a technical solution becomes available.
Treatment
* 60 Gy/50 fx / 10W-1 at 1.2 Gy/fx
o i.e. EQD2 tumor=56 Gy, EQD2 late=50.4 Gy at α/β= 10 and 3, respectively
* Proton radiotherapy
* Concomitant cisplatin for eligible patients\*
* Nimorazole recommended for SCC\* \*The concurrent medical treatment (weekly cisplatin and nimorazole) are prescribed according to the national treatment guidelines, and are not part of the experimental treatment.
Endpoints
* Primary:
o Any new late toxicity grade \>=3 according to CTC AE 5.0
* Secondary
* Side effects according to DAHANCA scoring system
* Quality of life and PROM according to EORTC C30 and HN43
* Loco-regional control (LRC)
* Overall survival (OS)
Derived projects
* Morbidity (NTCP) modeling for cumulative doses
* Metrics for uncertainties regarding cumulative doses
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Re-Irradiation with protons
60 Gy in 50 fraktions, 10 weekly with protons
Re-irradiation
Cisplatin for all eligible patients, nimorazole for all SCC
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Re-irradiation
Cisplatin for all eligible patients, nimorazole for all SCC
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Available dose plan from primary radiotherapy course
* Comparative dose plan with advantages for proton radiotherapy e.g. integral dose
* Dmax dose (0.03 cm3) on the cumulated photon dose plan≥90 Gy
* Complete Response (CR)\* after initial therapy, except in the case where the recurrence is considered a geometric miss (recurrence center of mass (COM) outside the 95% of prescription dose.
* Inoperable or salvage surgery with R1/R2 resection, extranodal extension (ENE) or extensive soft tissue infiltration
* Absence of distant metastasis at both
* clinical examination AND
* PET-CT or CT of thorax and upper abdomen
* Life expectancy due to age and co-morbidity of \>=1 year. The general condition must be sufficient to tolerate persistent significant side effects, e.g. tube or cannulae
* PS\<=2 (WHO See appendix)
Exclusion Criteria
* Lymphoma or malignant melanoma
* Inability to attend full course of radiotherapy or follow-up visits in the outpatient clinic
* As of 2019, patients with tracheal cannulas are excluded due to dose uncertainties. This may change if a technical solution becomes available.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Danish Head and Neck Cancer Group
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kenneth Jensen
Role: PRINCIPAL_INVESTIGATOR
Danish Centre for Particle Therapy
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Danish Center for Particle Therapy
Aarhus, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Dahanca 37
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.